Postdoctoral fellow Memorial Sloan Kettering Cancer Center Spain
Gabriel Espinosa Carrasco, Ph.D., is a seasoned immunologist renowned for his research on T cell dysfunction and immunotherapy. With a robust background in biological sciences and immunology, he has contributed significantly to understanding how different immune cell populations interact to combat cancer and autoimmune diseases. His career is marked by his leadership abilities and a strong network of collaborators in the immunology field.
Profile
Scopus
Education 🎓
Dr. Espinosa Carrasco holds a Ph.D. in Biological Sciences and Immunology from the University of Montpellier (2011-2016). He earned his Master’s in Advanced Immunology from the University of Barcelona in 2011 and a Bachelor’s degree in Biology from the Autonomous University of Barcelona in 2010.
Experience 🧑🔬
Currently, Dr. Espinosa Carrasco is a Post-doctoral Scholar at the Cancer Virotherapy and Immunotherapy Group at Bellvitge Institute for Biomedical Research (IDIBELL). He previously held a postdoctoral position at Memorial Sloan-Kettering Cancer Center, where he worked on projects related to intratumoral immune triads. His Ph.D. research at INSERM Unit 1183 focused on T cell interactions in autoimmune diabetes.
Research Interests 🔬
Dr. Espinosa Carrasco’s research interests lie in the development of new immunotherapies for solid tumors. He focuses on strategies to reverse T cell dysfunction, particularly the role of CD4 and CD8 T cells in tumor immunity. His work includes studying immune cell triads to enhance antitumor responses.
Awards 🏆
Dr. Espinosa Carrasco has received numerous accolades, including the 2024 Best Researcher Award (provisionally), a grant from the Ludwig Center for Basic and Translational Immunology, and the Third Prize Poster Presentation Award at the Tumor Microenvironments Symposium in 2019. He was also an invited seminar speaker at Georgetown University in 2017.
Publications Top Notes📚
Gabriel Espinosa-Carrasco et al. “Intratumoral immune triads are required for immunotherapy-mediated elimination of solid tumors.” Cancer Cell, 2024. 10.1016/j.ccell.2024.05.025 (Cited by 25 articles).
Mojdeh Shakiba, Gabriel Espinosa-Carrasco et al. “TCR signal strength defines distinct mechanisms of T cell dysfunction and cancer evasion.” J Exp Med, 2022. 10.1084/jem.20201966 (Cited by 40 articles).
Sofia V. Gearty, Gabriel Espinosa-Carrasco et al. “An autoimmune stem-like CD8 T cell population drives type 1 diabetes.” Nature, 2022. 10.1038/s41586-021-04155-4 (Cited by 50 articles).
Gabriel Espinosa-Carrasco et al. “Integrin beta 1 optimizes diabetogenic T cell migration and function in the pancreas.” Frontiers in Immunology, 2018. 10.3389/fimmu.2018.01156 (Cited by 30 articles).
Gabriel Espinosa-Carrasco et al. “CD4+ T helper cells play a key role in maintaining diabetogenic CD8+ T cell function in the pancreas.” Frontiers in Immunology, 2018. 10.3389/fimmu.2018.02001 (Cited by 35 articles).